In addition, since diseases other than polio (e.g., Guillain-Barre Syndrome) also lead to clinical presentation of AFP, comparisons between AFP sample collection rates and expected AFP baseline rates provide a means to assess the quality of the AFP surveillance system for specific populations. The gene discussed is AFP; the disease is Guillain-Barre syndrome.